Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Jan 12, 2018 11:55am

152 Views

Post# 27342382

RE:Investor Presentation updated

My take away
"Phase 2b dose-ranging efficacy study: Top-line results anticipated in Q4/18"
- I think they pushed this back a Q, thats fine. If i recal it was expected Q3 earlier.
The bigger takeaway:
"Antibe expects to begin global partnering discussions for ATB-346 in Q1 2018 subsequent to the release of the Phase 2 GI safety data"

Glad to see that is still the plan and that they are not waiting for Phase 2b. Sure that might get them more money if they wait, but I'm good to cash out early.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity